NBRV News and Press, Nabriva Therapeutics plc From 05/06/21

Nabriva Therapeutics (NBRV): Q1 GAAP EPS of -$0.53 beats by $0.14.Revenue of $2.52M (+219.0% Y/Y) beats by $0.27M.Press Release For further details see: Nabriva Therapeutics EPS beats by $0.14, beats on revenue

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021...

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter fi...

Biotech Penny Stocks to Watch This Month Penny stocks are well-known for their higher level of risk in the stock market today. The problem here is that the risk can quickly deter traders and investors from even exploring the topic. This is why research is so important. Just taking a dar...

Nabriva Therapeutics ([[NBRV]] +1.4%) announces that it has begun exclusive distribution of skin treatment SIVEXTRO (tedizolid phosphate) in the United States.SIVEXTRO was approved by the U.S. FDA in 2014, and is indicated in adults and pediatric patients 12 years of age and older f...

- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopha...

Nabriva Therapeutics plc (NASDAQ:NBRV) traded at a new 52-week low today of $1.44. So far today approximately 2 million shares have been exchanged, as compared to an average 30-day volume of 3.2 million shares. Nabriva Therapeutics plc (NASDAQ:NBRV) has potential upside of 21.0% based on...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroe...

Gainers: Zhongchao (ZCMD) +53%, Immatics (IMTX) +42%, Lipocine (LPCN) +23%, FSD Pharma (HUGE) +18%, Nabriva Therapeutics (NBRV) +18%.Losers: SunLink Health Systems (SSY) -28%, Rubius Therapeutics (RUBY) -17%, CHF Solutions CHFS&...

FSD Pharma (HUGE +52% on licensing deal for veterinary drugs in dogs and cats.Zhongchao (ZCMD +49% after contract renewal with China Association of Health Promotion and Education and GlaxoSmithKline.Immatics N.V. (IMTX +24% on announcing a clinical data update fr...